One-year follow-up of Graves' disease treatment by four different protocols of radioiodine administration

Panminerva Medica

Volumn 42, Issue 4, 2000, Pages 241-245

  Calegaro, J U M ^a,b   De Freitas Gomes, E ^a   Bae, S H ^a   Ulyssea, R ^a   Casulari, L A ^a  

^a HOSPITAL UNIVERSITÁRIO DE BRASÍLIA   (Brazil)

^b HOSPITAL DE BASE DO DISTRITO FEDERAL   (Brazil)

Author keywords

Antithyroid agents; Graves' disease; Hyperthyroidism; Hypothyroidism; Iodine, radioisotopes; Treatment outcome

Indexed keywords

ANTITHYROID AGENT; RADIOACTIVE IODINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; FEMALE; FOLLOW UP; GRAVES DISEASE; HUMAN; MALE; MIDDLE AGED;

ADOLESCENT; ADULT; ANTITHYROID AGENTS; CHILD; FEMALE; FOLLOW-UP STUDIES; GRAVES DISEASE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED;

EID: 0034573313     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Becker DV. Choice of therapy for Graves' hyperthyroidism. N Engl J Med 1984;311:464-6.
2. Farrar JJ, Toft AD. Iodine-131 treatment of hyperthyroidism: current issues. Clin Endocrinol 1991;35:207-12.
3. Franklyn JA. The management of hyperthyroidism. N Engl J Med 1994;330:1731-8.
4. Franklyn JA, Sheppard MC. Radioiodine for hyperthyroidism. Perhaps the best option. BMJ 1992;305:727-8.
5. Klein I, Becker DV, Levey GS. Treatment of hyperthyroid disease. Ann Intern Med 1994;121:281-8.
6. Rivkees SA, Sklar C, Freemark M. The management of Graves' disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab 1998;83:3767-76.
7. Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Daniels G et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. JAMA 1995;273:808-12.
8. Romaldini JH, Bromberg N, Werner RS, Tanaka LM, Rodrigues HF, Werner MC et al. Comparison of effects of high and low dosage regimens of antithyroid drugs in the mangement of Graves' hyperthyroidism. J Clin Endocrinol Metab 1983;57:563-70.
9. Romaldini JH, Bomberg N, Werner MC. Tratamento da doença de Graves com drogas antitiroidianas. Arq Bras Endocrinol Metab 1994;38:1-9.
10. Pimentel Filho FR, Goldman J, Liberman B. Terapêutica descontínua como fator precipitante de reações adversas ao propiltiouracil. Arq Bras Endocrinol Metab 1994;38:130-4.
11. Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the Cooperative Thyrotoxicosis Therapy Follow-up Study. J Clin Endocrinol Metab 1974;38:976-98.
12. 131I) in the treatment of hyperthyroidism. In: Beckers C, editor. Thyroid diseases. Paris: Pergamon Press, 1982:145-58.
13. Dvorkin HJ, Meier DA, Kaplan M. Advances in the management of patients with thyroid diseases. Sem Nucl Med 1995;35:205-20.
14. Hall P, Boice JD Jr, Berg G, Bjelkengren G, Ericsson U-B, Hallquist A et al. Leukaemia incidence after iodine-131 exposure. Lancet 1992;340:1-4.
15. Kendall-Taylor P, Keir MJ, Ross WM. Ablative radioiodine therapy for hyperthyroidism: long term follow-up study. BMJ 1984;289: 361-3.
16. Goldman MB, Maloof F, Monson RR, Aschengrau A, Cooper DS, Ridgway EC. Radioactive iodine therapy and breast cancer. A follow-up study of hyperthyroid women. Am J Epidemiol 1988;127: 969-80.
17. 131I for thyroid cancer. J Nucl Med 1976;17:460-4.
18. 131I therapy for hyperthyroidism in the first trimester of pregnancy. J Nucl Med 1975;17:146-9.
19. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998;338:73-8.
20. Marcocci C, Bartalena L, Pinchera A. Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy? J Endocrinol Invest 1998;21:472-5.
21. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren J-G, Blomgren H et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med 1992;326:1733-8.
22. Sridama V, DeGroot LJ. Treatment of Graves' disease and the course of ophthalmopathy. Am J Med 1989;87:70-3.
23. 131I therapy for Graves' disease. N Engl J Med 1984;311:426-32.
24. Franklyn JA, Daykin J, Holder R, Sheppard MC. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism. Q J Med 1995;88:175-80.
25. Eriksson E, Eriksson K, Wahlberg P. Treatment of hyperthyroidism with standard doses of radioiodine aiming at ablation. Acta Med Scand 1985;217:55-60.
26. Franklyn JA, Daykin J, Droic Z, Farmer M, Sheppard MC. Long-term follow-up of treatment of thyrotoxicosis by three different methods. Clin Endocrinol 1991;34:71-6.
27. 131I therapy in Graves' disease. JAMA 1973;224:1610-3.
28. 131I. Arch Intern Med 1975;135:673-5.
29. Sawers JSA, Toft AD, Irvine WJ, Brown NS, Seth J. Transient hypothyroidism after iodine-131 treatment of thyrotoxicosis. J Clin Endocrinol Metab 1980;50:226-9.
30. Hancock LD, Tuttle RM, LeMar H, Bauman J, Patience T. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease. Clin Endocrinol 1997;47:425-30.
31. Yoshida K, Aizawa Y, Kaise N, Fukazawa H, Kiso Y, Sayama N et al. Relationship between thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins years after administration of radioiodine for Graves' disease: restrospective clinical survey. J Endocrinol Inves 1996;19:682-6.